CA2892965C - Lyophilized formulation of tat-nr2b9c - Google Patents

Lyophilized formulation of tat-nr2b9c Download PDF

Info

Publication number
CA2892965C
CA2892965C CA2892965A CA2892965A CA2892965C CA 2892965 C CA2892965 C CA 2892965C CA 2892965 A CA2892965 A CA 2892965A CA 2892965 A CA2892965 A CA 2892965A CA 2892965 C CA2892965 C CA 2892965C
Authority
CA
Canada
Prior art keywords
nr2b9c
tat
lyophilized formulation
formulations
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2892965A
Other languages
English (en)
French (fr)
Other versions
CA2892965A1 (en
Inventor
Jonathan David Garman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NoNO Inc
Original Assignee
NoNO Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NoNO Inc filed Critical NoNO Inc
Publication of CA2892965A1 publication Critical patent/CA2892965A1/en
Application granted granted Critical
Publication of CA2892965C publication Critical patent/CA2892965C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2892965A 2012-11-28 2013-11-25 Lyophilized formulation of tat-nr2b9c Active CA2892965C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261730952P 2012-11-28 2012-11-28
US61/730,952 2012-11-28
PCT/US2013/071755 WO2014085349A1 (en) 2012-11-28 2013-11-25 Lyophilized formulation of tat-nr2b9c

Publications (2)

Publication Number Publication Date
CA2892965A1 CA2892965A1 (en) 2014-06-05
CA2892965C true CA2892965C (en) 2021-06-01

Family

ID=50828392

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2892965A Active CA2892965C (en) 2012-11-28 2013-11-25 Lyophilized formulation of tat-nr2b9c

Country Status (18)

Country Link
US (1) US20140162957A1 (enExample)
EP (1) EP2925338B8 (enExample)
JP (1) JP6427104B2 (enExample)
KR (1) KR102166374B1 (enExample)
CN (2) CN105101986B (enExample)
AU (1) AU2013352437B2 (enExample)
CA (1) CA2892965C (enExample)
DK (1) DK2925338T3 (enExample)
ES (1) ES2725598T3 (enExample)
HR (1) HRP20190707T1 (enExample)
HU (1) HUE043820T2 (enExample)
LT (1) LT2925338T (enExample)
MX (1) MX365325B (enExample)
PL (1) PL2925338T3 (enExample)
PT (1) PT2925338T (enExample)
SI (1) SI2925338T1 (enExample)
TR (1) TR201905787T4 (enExample)
WO (1) WO2014085349A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
US11039621B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039620B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US9622483B2 (en) 2014-02-19 2017-04-18 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
WO2015181757A1 (en) * 2014-05-28 2015-12-03 Nono Inc. Lyophilized formulation of tat-nr2b9c with acetylation scavenger
SMT202000307T1 (it) 2014-05-28 2020-07-08 Nono Inc Sale cloruro di tat-nr2b9c
US20190064147A1 (en) * 2015-01-18 2019-02-28 Biogen Ma Inc. Formulations and screening of biological therapeutic agents
WO2017185250A1 (zh) * 2016-04-27 2017-11-02 拜西欧斯（北京）生物技术有限公司 兴奋性神经毒性相关损伤的治疗方法
CN106619170A (zh) * 2016-10-26 2017-05-10 暨南大学 包含stp和生长因子的活性组合物及其化妆品或护肤品
CN110627877A (zh) * 2019-09-25 2019-12-31 成都奥达生物科技有限公司 一种psd-95抑制剂
CA3166998A1 (en) * 2020-01-09 2021-07-15 Nono Inc. Plasmin-resistant peptides for treating stroke and related conditions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605884A (en) * 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
US20080119412A1 (en) * 2003-12-23 2008-05-22 Nono Inc. Polypeptides for Modulating Binding of Trp Channel Proteins and Trp- Associated Proteins
GB0329918D0 (en) * 2003-12-24 2004-01-28 West Pharm Serv Drug Res Ltd Intranasal compositions
US7588911B2 (en) * 2005-06-23 2009-09-15 Arbor Vita Corporation Assays for detecting inhibitors of binding between COX-2 and PDZ proteins
US8633160B2 (en) * 2005-12-30 2014-01-21 Nono Inc. Small molecule inhibitors of PDZ interactions
BRPI0711193A2 (pt) * 2006-05-05 2013-06-18 Transtech Pharma Inc proteÍnas de fusço rage, formulaÇÕes e mÉtodos de uso dos mesmos
EP1884521A1 (en) * 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
US8080518B2 (en) * 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
CN102202677A (zh) * 2008-09-03 2011-09-28 阿尔伯维塔公司 治疗疼痛的活性剂和方法
US8099602B2 (en) * 2008-09-26 2012-01-17 Mykonos Software, Inc. Methods for integrating security in network communications and systems thereof
CA2765171C (en) * 2009-06-10 2018-10-02 Nono Inc. Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
EP2440230B1 (en) * 2009-06-10 2020-11-11 NoNO Inc. Treatment regimes for treatment of neurological disease
WO2012021854A2 (en) * 2010-08-12 2012-02-16 Nono, Inc. Treatment of penetrative injury to the brain

Also Published As

Publication number Publication date
LT2925338T (lt) 2019-05-10
CN109106941A (zh) 2019-01-01
BR112015012422A2 (pt) 2017-09-12
PL2925338T3 (pl) 2019-11-29
US20140162957A1 (en) 2014-06-12
EP2925338A4 (en) 2016-05-25
SI2925338T1 (sl) 2019-09-30
EP2925338A1 (en) 2015-10-07
HK1215793A1 (en) 2016-09-15
ES2725598T3 (es) 2019-09-25
CN105101986A (zh) 2015-11-25
MX365325B (es) 2019-05-29
JP2016502537A (ja) 2016-01-28
CN105101986B (zh) 2018-09-25
KR20150094656A (ko) 2015-08-19
KR102166374B1 (ko) 2020-10-15
AU2013352437B2 (en) 2018-04-12
CA2892965A1 (en) 2014-06-05
HRP20190707T1 (hr) 2019-10-04
TR201905787T4 (tr) 2019-05-21
PT2925338T (pt) 2019-05-31
HUE043820T2 (hu) 2019-09-30
DK2925338T3 (da) 2019-05-06
JP6427104B2 (ja) 2018-11-21
AU2013352437A1 (en) 2015-07-09
EP2925338B1 (en) 2019-03-27
WO2014085349A1 (en) 2014-06-05
EP2925338B8 (en) 2019-05-22
MX2015006784A (es) 2015-10-29

Similar Documents

Publication Publication Date Title
MX365325B (es) Formulación liofilizada de tat-nr2b9c.
MX2020009633A (es) Sal de cloruro de tat-nr2b9c.
ECSP24034690A (es) Formulación tópica para un inhibidor de jak
WO2012103038A9 (en) Nanoparticle compositions, formulations thereof, and uses therefor
WO2011061330A3 (de) Verwendung physiologischer kühlwirkstoffe und mittel enthaltend solche wirkstoffe
CA2894891A1 (en) Boronic acid derivatives and therapeutic uses thereof
WO2012018446A3 (en) Anchor delivery system
WO2012154679A8 (en) Tricyclic pyrazole sulfonamide compounds and methods of making and using same
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
WO2012035429A3 (en) Remotely controlled drug delivery systems
WO2012112410A3 (en) Micronized placental tissue compositions and methods for making and using the same
WO2012080729A3 (en) Casein kinase 1delta (ck1delta) inhibitors and their use in the treatment of neurodegenerative diseases such as tauopathies
WO2012024233A3 (en) Zwitterionic lipids
HK1206726A1 (en) Imidazotriazinone compounds
MX363462B (es) Diagnostico, prevencion y tratamiento de enfermedades de la articulacion.
WO2013003827A3 (en) Macrogol 15 hydroxystearate formulations
PH12014501866A1 (en) Thermosensitive nanoparticle formulations and method of making the same
MX357759B (es) Formulaciones y formas de dosificacion de fosfolipidos oxidados.
WO2012085284A3 (en) High drug load pharmaceutical formulations comprising dronedarone and its pharmaceutically acceptable salts
BR112014009242A2 (pt) nanossuspensão farmacêutica
WO2011076840A3 (en) Aerosol formulation for copd
WO2012004588A3 (en) Therapeutic agents 976
HK1210173A1 (en) Substituted 6-amino-nicotinamides bearing an oh-containing group as kcnq2/3 modulators
IN2012CH05549A (enExample)
WO2014039412A8 (en) Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180706

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250527

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20251103

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251106